TP73 Gene: Tumor Protein p73
A member of the p53 family of transcription factors involved in cell cycle regulation, apoptosis, and tumor suppression.
Gene Information Card
| Symbol | TP73 |
|---|---|
| Full Name | tumor protein p73 |
| Gene Type | protein-coding |
| Chromosomal Location | 1p36.32 |
| NCBI Gene ID | 7161 ncbi.nlm.nih.gov/gene/7161 |
| Ensembl ID | ENSG00000073282 |
| UniProt ID | O15350 |
| OMIM ID | 601603 |
| HGNC ID | 12003 |
| Aliases | p73, P73, TP73L, CTNNB1, TAp73, DeltaNp73 |
Description
TP73 (tumor protein p73) is a member of the p53 family of transcription factors. It encodes multiple isoforms due to alternative promoter usage and splicing, including full-length TAp73 (pro-apoptotic, tumor suppressive) and N-terminally truncated DeltaNp73 (anti-apoptotic, oncogenic). TP73 regulates cell cycle arrest, apoptosis, and differentiation, and is involved in neurodevelopment, ciliogenesis, and genomic stability. Mutations and altered expression of TP73 are implicated in various cancers and developmental disorders.
Disease Associations
| Disease category | Pathophysiological mechanism | Genomic evidence |
|---|---|---|
| Breast cancer | Loss of TAp73 expression or overexpression of DeltaNp73 promotes tumorigenesis | PMID: 15601829; COSMIC |
| Neuroblastoma | TP73 deletions and reduced expression at 1p36 locus are frequent | PMID: 10408532; ClinVar |
| Lung cancer | TP73 promoter methylation and isoform imbalance contribute to pathogenesis | PMID: 12007225; COSMIC |
| Colorectal cancer | TP73 mutations and altered splicing linked to poor prognosis | PMID: 12460986; COSMIC |
| Ovarian cancer | TP73 overexpression of DeltaNp73 associated with chemoresistance | PMID: 15601829; ClinVar |
Expression Profile
Tissue Expression
| Tissue | nTPM | level |
|---|---|---|
| Brain | 2.1 | Low |
| Heart | 0.8 | Not detected |
| Liver | 0.5 | Not detected |
| Kidney | 1.2 | Low |
| Lung | 1.5 | Low |
| Breast | 1.0 | Low |
| Colon | 0.9 | Not detected |
| Ovary | 1.3 | Low |
| Testis | 3.4 | Medium |
| Placenta | 2.8 | Medium |
Cell Line Expression
| Cell Line | nTPM | Notes |
|---|---|---|
| HEK293 | 2.5 | Embryonic kidney; moderate expression |
| HeLa | 1.8 | Cervical carcinoma; low expression |
| MCF7 | 1.2 | Breast cancer; low expression |
| A549 | 1.6 | Lung cancer; low expression |
| SH-SY5Y | 3.0 | Neuroblastoma; moderate expression |
| HCT116 | 1.4 | Colorectal cancer; low expression |
Data source：Human Protein Atlas（proteinatlas.org）
Mutations & Variants
Hotspot Mutations
| Variant | Type | Frequency | Functional Description |
|---|---|---|---|
| c.1A>G (p.Met1?) | missense | <0.1% | Loss of start codon; likely loss of function |
| c.818G>A (p.Arg273His) | missense | <0.1% | DNA-binding domain; reduced transactivation |
| c.832C>T (p.Arg278Trp) | missense | <0.1% | DNA-binding domain; loss of function |
| c.977_978insA (p.Tyr326*) | frameshift | <0.1% | Premature stop; loss of function |
| c.1168C>T (p.Arg390*) | nonsense | <0.1% | Truncation; loss of function |
Mutation functional classification
Loss of Function (LOF)
Missense and nonsense mutations in the DNA-binding domain (e.g., p.Arg273His, p.Arg278Trp, p.Arg390*) impair transactivation of target genes, reducing apoptosis and cell cycle arrest.
Gain of Function (GOF)
Overexpression of DeltaNp73 isoforms acts as a dominant-negative inhibitor of p53 and TAp73, promoting cell survival and proliferation.
Dominant Negative (DN)
DeltaNp73 isoforms lack the N-terminal transactivation domain and can heterodimerize with p53 and TAp73, blocking their transcriptional activity.
View complete mutation data：
Gene Ontology (GO)
Pathways
• hsa04115 - p53 signaling pathway
• hsa04210 - Apoptosis
• hsa04110 - Cell cycle
• hsa05200 - Pathways in cancer
• hsa05202 - Transcriptional misregulation in cancer
Protein Summary
TP73 encodes the tumor protein p73, a transcription factor with a DNA-binding domain, a tetramerization domain, and a C-terminal SAM domain. It shares structural homology with p53 and p63. The full-length TAp73 isoform activates pro-apoptotic and cell cycle arrest genes (e.g., BAX, CDKN1A/p21), while the DeltaNp73 isoform lacks the N-terminal transactivation domain and acts as a dominant-negative inhibitor. Post-translational modifications include phosphorylation, acetylation, and ubiquitination, regulating stability and activity. TP73 is essential for neurodevelopment, ciliogenesis, and genomic stability.
Related Services
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| TP73 Knockout HEK293 Cell Line | EDJ-KQ1393 | Human | 7161 | Details Get a Quote |
| TP73 Knockout HCT 116 Cell Line | EDJ-KQ19570 | Human | 7161 | Details Get a Quote |
| TP73 Knockout HeLa Cell Line | EDJ-KQ20916 | Human | 7161 | Details Get a Quote |
| TP73 Knockout A-549 Cell Line | EDJ-KQ63169 | Human | 7161 | Details Get a Quote |
Displaying Records 1 To 4 Of 4 Records
